FAQs & How to use this site
Home | About Us | Contact Us
The Front Line
The Front Line: Charles D. Blanke, MD, SWOG Chair
ABOUT

PREVIOUS POSTS October 2017

September 2017 August 2017 July 2017 June 2017 May 2017 April 2017 March 2017 February 2017 January 2017 December 2016 November 2016 October 2016 September 2016 August 2016 July 2016 JUNE 2016 MAY 2016 APRIL 2016 MARCH 2016 FEB 2016 JAN 2016 DEC 2015 NOV 2015 OCT 2015 SEP 2015 AUG 2015 JUL 2015 JUN 2015 MAY 2015 APR 2015 MAR 2015 FEB 2015 JAN 2015 DEC 2014 NOV 2014 OCT 2014 SEP 2014 AUG 2014 JUL 2014 JUN 2014 MAY 2014 APR 2014 MAR 2014 FEB 2014 JAN 2014 DEC 2013 NOV 2013 OCT 2013 SEP 2013 AUG 2013 JUL 2013

Office Hours with Industry Partners in San Francisco

by Guest Blogger Lee Ellis, M.D., SWOG Vice-Chair for Translational Medicine

Mar 13, 2015 - In order to better understand targets and pathways and how to use this knowledge to formulate innovative clinical trials in oncology, we must have open discussions with our colleagues in industry and pharma. In this regard, we have arranged to have several of our colleagues in industry host "office hours" at the meeting in San Francisco on Friday, May 1. These industry clinical investigators and scientists will be able to work with us to help determine the best use of agents and biomarkers in formulating the next generation of clinical trials to be led by SWOG.

Ahead of these conversations, our colleagues from industry are providing lists of drugs and biomarkers that they wish to discuss with SWOG investigators in the planning of clinical trials. Some of these are detailed below. Others will be posted soon to the SWOG Group Meeting web page.

INDUSTRY OFFICE HOURS AT SWOG'S SPRING 2015 GROUP MEETING
MEET WITH: TOPICS for DISCUSSION:
AstraZeneca
Aiman Shalabi, Pharm.D.
To be posted online.
Celgene
Gilbert Jirau-Lucca, M.S.
Agents: paclitaxel (Abraxane), lenalidomide (Revlimid), and pamilomide (Pomalyst)
Foundation Medicine
Deborah Morosini, M.D.
Platform: FoundationOne genomic profiling
Genentech
Daniel Chen, M.D., Ph.D.
Agent: MPDL3280A (anti-PD-L1)
Genomic Health
Steven Shak, M.D.
Platform: Oncotype DX - Recurrence risk assessment assay (for breast, colon, and prostate cancers)
Lilly
Scott Saxman, M.D.
To be posted online.
Novartis
Janet Lyle, Pharm.D., and Stacie Ittershagen, Ph.D.
Agents: Small molecule TK inhibitors including ALK, c-MET, EGFR T790M, P13K, CDK4/6, HDAC, FLT3, FGFR
Takeda
Kelly Terrill, Pharm.D.
To be posted online.

All industry office hours will be held on Friday, May 1. Morning and afternoon hours will be available. Sign up for an appointment when you register for the Group Meeting (if you've already registered, you can revisit the registration page and add appointments to your registration).

Thank you to our colleagues and collaborators in industry who will be attending the SWOG Group Meeting to help strengthen the channels of communication between their organizations and the publicly funded National Clinical Trials Network. These types of partnerships are vital if we hope to continue making progress in cancer care for our patients.


P.S.: Dr. Cathy Eng, Chair of SWOG's Young Investigators Task Force, is planning additional sessions of the extremely popular "Navigating SWOG" round tables that she led last fall. Stay tuned for more information!

 

 
     
SWOG Logo Disclaimer | Copyright ©2000-2017 SWOG. All rights reserved.
Design by nuMedia Group Inc. | Hosting by WorldPost Technologies, Inc.
SWOG is FISMA CertifiedSWOG is FISMA Certified